Development of a Novel Anti-Siglec-15 Antibody for Tumor Immunotherapy.

Immunotargets Ther · 2025 · PMC12704181 · PMID 41403877

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Research on siglec-15-targeting antibodies is highly significant for evaluating the normalization of immunotherapy within the tumor immune microenvironment, improving tumor treatment strategies, and enhancing therapeutic efficacy.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.